Hill-Rom (HRC) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Hill-Rom (NYSE:HRC) from a sell rating to a hold rating in a report released on Tuesday morning.

According to Zacks, “Hill-Rom exited the first quarter of fiscal 2019 on a strong note. The company saw a solid year-over-year increase in revenues on robust domestic growth, driven by sturdy performance by Patient Support Systems and Front Line Care. Hill-Rom has recorded around $100 million in new product revenues in the reported quarter. We are also upbeat about Hill-Rom’s integration of EarlySense’s continuous contact-free heart rate and respiratory rate sensing and analytics technology with its Centrella Smart+ bed platform in the reported quarter. Also, the tie-up with Microsoft to make advanced, relevant and actionable point-of-care data and solutions buoys optimism. Overall, Hill-Rom has outperformed its industry in the past three months. However, foreign exchange and a tough competitive landscape remain headwinds. Also, Hill-Rom’s global revenues declined in the quarter.”

Other equities analysts have also recently issued research reports about the stock. ValuEngine upgraded shares of Hill-Rom from a hold rating to a buy rating in a research report on Tuesday, November 6th. UBS Group assumed coverage on shares of Hill-Rom in a research report on Tuesday, November 27th. They set a buy rating and a $115.00 target price for the company. Raymond James lifted their target price on shares of Hill-Rom from $100.00 to $105.00 and gave the stock an outperform rating in a research report on Monday, November 5th. Barclays assumed coverage on shares of Hill-Rom in a research report on Monday, October 15th. They set an equal weight rating and a $95.00 target price for the company. Finally, Morgan Stanley cut their target price on shares of Hill-Rom from $100.00 to $98.00 and set an equal weight rating for the company in a research report on Wednesday, January 2nd. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $102.67.

Shares of NYSE HRC opened at $103.74 on Tuesday. The company has a quick ratio of 1.25, a current ratio of 1.70 and a debt-to-equity ratio of 1.17. Hill-Rom has a 52 week low of $79.36 and a 52 week high of $105.78. The stock has a market capitalization of $6.84 billion, a P/E ratio of 21.84, a P/E/G ratio of 1.45 and a beta of 0.95.

Hill-Rom (NYSE:HRC) last announced its quarterly earnings data on Friday, January 25th. The medical technology company reported $1.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.98 by $0.04. Hill-Rom had a net margin of 7.21% and a return on equity of 21.23%. The firm had revenue of $683.50 million during the quarter, compared to analysts’ expectations of $676.39 million. During the same quarter last year, the business earned $0.92 earnings per share. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, research analysts anticipate that Hill-Rom will post 5.06 EPS for the current fiscal year.

In other Hill-Rom news, SVP Andreas G. Frank sold 7,454 shares of Hill-Rom stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $95.76, for a total transaction of $713,795.04. Following the completion of the transaction, the senior vice president now owns 27,224 shares in the company, valued at $2,606,970.24. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.73% of the company’s stock.

Large investors have recently bought and sold shares of the company. Oakbrook Investments LLC raised its position in shares of Hill-Rom by 34.5% in the third quarter. Oakbrook Investments LLC now owns 8,967 shares of the medical technology company’s stock valued at $846,000 after buying an additional 2,300 shares during the last quarter. LSV Asset Management purchased a new stake in Hill-Rom in the third quarter valued at approximately $715,000. Vanguard Group Inc grew its holdings in Hill-Rom by 0.6% in the third quarter. Vanguard Group Inc now owns 5,916,827 shares of the medical technology company’s stock valued at $558,549,000 after purchasing an additional 34,369 shares during the period. TIAA CREF Investment Management LLC grew its holdings in Hill-Rom by 2.1% in the third quarter. TIAA CREF Investment Management LLC now owns 192,606 shares of the medical technology company’s stock valued at $18,182,000 after purchasing an additional 4,010 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Hill-Rom in the fourth quarter valued at approximately $299,000. 86.96% of the stock is owned by institutional investors and hedge funds.

About Hill-Rom

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Read More: How is a Moving Average Calculated?

Get a free copy of the Zacks research report on Hill-Rom (HRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.